NEW YORK (GenomeWeb) – A multi-omics R&D outfit is commercializing a mass spectrometry-based blood test for metabolites indicative of cardiovascular disease caused by plaque buildup, or atherosclerosis. 

Global Genomics Group (G3) plans to develop the test, called knowPlaque, simultaneously as a laboratory-developed test (LDT) and as a US Food and Drug Administration-approved kit. The test looks at a multiplex set of metabolites and uses an algorithm to rule out patients for atherosclerosis.